After a week of WHO granting the emergency Use Listing (EUL) to Bharat Biotech's Covaxin, The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.

Check the tweet here:

(SocialLY brings you all the latest breaking news, viral trends and information from social media world, including Twitter, Instagram and Youtube. The above post is embeded directly from the user's social media account and LatestLY Staff may not have modified or edited the content body. The views and facts appearing in the social media post do not reflect the opinions of LatestLY, also LatestLY does not assume any responsibility or liability for the same.)